SGK1 in Cancer: Biomarker and Drug Target.
Jonas CicenasEdita Meskinyte-KausilieneVigilijus JuknaArnas RimkusJokubas SimkusDiana SoderholmPublished in: Cancers (2022)
Serum- and glucocorticoid-regulated kinases (SGKs) are members of the AGC family of serine/threonine kinases, consisting of three isoforms: SGK1, SGK2, and SGK3. SGK1 was initially cloned as a gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells. It is upregulated in some cancers and downregulated in others. SGK1 increases tumor cell survival, adhesiveness, invasiveness, motility, and epithelial to mesenchymal transition. It stimulates tumor growth by mechanisms such as activation of K + channels and Ca 2+ channels, Na + /H + exchanger, amino acid and glucose transporters, downregulation of Foxo3a and p53, and upregulation of β-catenin and NFκB. This chapter focuses on major aspects of SGK1 involvement in cancer, its use as biomarker as well as potential therapeutic target.
Keyphrases
- signaling pathway
- papillary thyroid
- cell proliferation
- amino acid
- transcription factor
- protein kinase
- squamous cell
- epithelial mesenchymal transition
- emergency department
- squamous cell carcinoma
- escherichia coli
- gene expression
- staphylococcus aureus
- genome wide
- risk assessment
- pseudomonas aeruginosa
- biofilm formation
- lps induced
- dna methylation
- inflammatory response
- lymph node metastasis
- human health
- blood glucose
- candida albicans